RESUMEN
Objective@#To investigate the prevalence and predictive factors of malnourishment in patients with gynecologic cancer during chemotherapy. @*Methods@#A total of 101 patients treated with chemotherapy between April 2020 and February 2021 were interviewed using the patient-generated subjective global assessment (PG-SGA). Clinical and laboratory data were also collected. The total number of lymphocytes per cubic milliliter (total lymphocyte count, TLC) and serum albumin were calculated to provide an optimal cut-off point using receiver operating characteristic curves. Clinicopathological variables were compared using univariate and multivariate analyses to identify the independent predictive factors for malnourishment. @*Results@#The prevalence of good, moderate, and severe nourishment was 73.3%, 18.8%, and 7.9%, respectively. The optimal cut-off points for TLC and albumin were 1,450 cells/μL and for albumin was 3.9 g/dL. Univariate analysis indicated that the number of chemotherapy cycles ≤3, albumin level ≤3.95 g/dL, body mass index ≤25 kg/m2, TLC <1,450 cells/μL, anemia, and no neutropenia were significantly associated with malnutrition. However, only a serum albumin level ≤3.95 g/dL was independently associated with malnourishment. @*Conclusion@#Patients with gynecologic cancer treated with chemotherapy were occasionally found to be malnourished, with the independent predictive predictor being a blood albumin level less than or equal to 3.95 g/dL.
RESUMEN
3.38, PLR >210, CA125 >365, advanced stage, suboptimal disease, serous type, and ascites were significant predictive factors for platinum resistance. However, only NLR >3.38 and advanced stage were independent predictive factors with an adjusted odds ratio of 1.880 and 3.333, respectively. Regarding factors associated with poor survival outcomes, only PLR >210 and advanced stage were independent factors, with a hazard ratio of 1.578 and 3.994, respectively.CONCLUSION: High NLR and advanced stage were potential independent predictive factors for platinum resistance, whereas high PLR and advanced stage were potential independent predictive factors for poor survival outcomes.
Asunto(s)
Femenino , Humanos , Ascitis , Plaquetas , Quimioterapia , Trompas Uterinas , Linfocitos , Registros Médicos , Análisis Multivariante , Neutrófilos , Oportunidad Relativa , Neoplasias Ováricas , Platino (Metal) , Pronóstico , Estudios Retrospectivos , Curva ROCRESUMEN
Background: Several studies have demonstrated that anemia is one of the poor prognostic factors for cervical cancer patients treated with radiotherapy. We questioned the necessity of weekly hemoglobin level monitoring in these patients. This study was conducted to evaluate the value of weekly hemoglobin level measurement in cervical cancer patients receiving radiotherapy.Objective: To evaluate the value of weekly hemoglobin (Hb) level measurement in cervical cancer patients receiving radiotherapy.Materials and Methods: The medical records of cervical cancer patients admitted in gynecologic oncology ward between May 2000 and May 2002 were reviewed to evaluate the clinical characteristics and weekly Hb level. Measurement outcomes include grade 2-4 hematologic toxicity, Hb nadir, week of Hb nadir and the number of blood transfusion. Design: Descriptive study.Setting: Chiang Mai University Hospital.Results: There were 113 cervical cancer patients receiving radiotherapy in the study period. Fifty-four patients (47.8%) had Hb level at presentation \< 10 g/dL. Among these patients, grade 2-4 anemia was found in 21-30 patients per week with a mean of 23.5 (43.5%) in week 1-4. Between week 5-8, grade 2-4 anemia was found in 5-22 patients per week with a mean of 15.3 (28.3%). Among 59 patients with Hb level at presentation \> 10 g/dL, grade 2-4 anemia was found in 7-9 patients per week with a mean of 7.5 (12.7%) in the first 4 week. After week 4, grade 2-4 anemia was found in 3-8 patients per week with a mean of 5.8 (9.8%). Patients with Hb level at presentation \> 11 g/dL, grade 2-4 anemia was found in only 0.8% and 4.9% in week 1-4 and week 5-8, respectively. Fourty-seven patients (41.6%) received a blood transfusion. Among these patients, 42 patients (89.4%) had a Hb level at presentation \< 10 g/dL, the remaining 5 patients (10.6%) had a Hb level at presentation \> 10 g/dL(P \< 0.001). Only one patient with Hb level at presentation \> 11 g/dL received a blood transfusion. No blood transfusion was administered in patients with Hb at presentation \> 12 g/dL.Conclusions: For cervical cancer patients with Hb level at presentation \< 10 g/dL, weekly Hb level should be checked during radiotherapy. Among those with Hb level at presentation \> 11 g/dL, Hb level may be checked less frequently.Key words: Hemoglobin level, cervical cancer, radiotherapy
RESUMEN
OBJECTIVE: Retrospective evaluation of the outcome of stage IVB, recurrent or persistent cervical cancer treated with cisplatin and generic topotecan (CT) in a tertiary care hospital in Thailand. METHODS: The medical records of patients treated with CT regimen at Chiang Mai University Hospital between January 2005 and December 2007 were reviewed and analyzed. The treatment protocol consisted of IV topotecan 0.75 mg/m2 on days 1, 2, and 3; combined with cisplatin 50 mg/m2 IV on day 1 and repeated every 21 days until progression or unacceptable toxicity for a maximum of 6 cycles. The outcomes were evaluated based on the response rate, progression free survival (PFS), and overall survival (OS) by using the World Health Organization criteria. The adverse effects of the treatments were also determined. RESULTS: Twenty-one cervical cancer patients received the CT regimen. The tumor response rate was 28.6%. The median PFS and OS was 4 and 11 months, respectively. With 87 cycles of chemotherapy, the most common grade 3 & 4 hematologic toxicity was neutropenia (57.9%). CONCLUSION: Advanced and recurrent cervical cancer patients treated with cisplatin and generic topotecan had a favorable outcome with manageable toxicity.